116 related articles for article (PubMed ID: 24879473)
1. Do Sociodemographic Factors Influence Outcome in Prostate Cancer Patients Treated With External Beam Radiation Therapy?
Movsas A; Ibrahim R; Elshaikh MA; Lamerato L; Lu M; Sitarik A; Pradhan D; Walker EM; Stricker H; Freytag SO; Chetty IJ; Movsas B; Siddiqui F
Am J Clin Oncol; 2016 Dec; 39(6):563-567. PubMed ID: 24879473
[TBL] [Abstract][Full Text] [Related]
2. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
3. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
[TBL] [Abstract][Full Text] [Related]
4. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
[TBL] [Abstract][Full Text] [Related]
5. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.
Zumsteg ZS; Spratt DE; Romesser PB; Pei X; Zhang Z; Polkinghorn W; McBride S; Kollmeier M; Yamada Y; Zelefsky MJ
Eur Urol; 2015 Jun; 67(6):1009-1016. PubMed ID: 25308970
[TBL] [Abstract][Full Text] [Related]
6. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
7. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
[TBL] [Abstract][Full Text] [Related]
8. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.
Jabbari S; Weinberg VK; Shinohara K; Speight JL; Gottschalk AR; Hsu IC; Pickett B; McLaughlin PW; Sandler HM; Roach M
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):36-42. PubMed ID: 19409729
[TBL] [Abstract][Full Text] [Related]
9. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
Zelefsky MJ; Marion C; Fuks Z; Leibel SA
J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785
[TBL] [Abstract][Full Text] [Related]
10. Reliability of prostate-specific antigen-marker in determining biochemical failure during the first 2 years after external beam radiation therapy and hormone therapy in patients with non-operated prostate cancer.
Vigna-Taglianti R; Russi EG; Boriano A; Gianello L; Denaro N; Lucio F; Arena G; Buglione M; Pergolizzi S; Ricardi U; Magrini S
Urol Oncol; 2014 Jan; 32(1):30.e1-7. PubMed ID: 23410946
[TBL] [Abstract][Full Text] [Related]
11. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
[TBL] [Abstract][Full Text] [Related]
12. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis.
Pickles T; Keyes M; Morris WJ
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):43-9. PubMed ID: 19570619
[TBL] [Abstract][Full Text] [Related]
13. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
14. Long-term results in three-dimensional conformal radiotherapy of localized prostate cancer at moderate dose (66 Gy).
Goldner G; Wachter S; Wachter-Gerstner N; Dieckmann K; Pötter R
Strahlenther Onkol; 2006 Sep; 182(9):537-42. PubMed ID: 16944376
[TBL] [Abstract][Full Text] [Related]
15. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
16. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
17. Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapy.
Pai HH; Ludgate C; Pickles T; Paltiel C; Agranovich A; Berthelet E; Duncan G; Kim-Sing C; Kwan W; Lim J; Liu M; Tyldesley S
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):990-8. PubMed ID: 16682135
[TBL] [Abstract][Full Text] [Related]
18. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
[TBL] [Abstract][Full Text] [Related]
19. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
20. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]